Guardant Health is a precision oncology company focused on helping conquer cancer through use of its proprietary tests, data sets and analytics. Co.'s Guardant Health Oncology Platform is designed to utilize its capabilities in technology, clinical development, regulatory and reimbursement. Co. engages in the clinical liquid biopsy market with its tests. Co.'s Guardant360 test is a molecular diagnostic test measuring cancer-related genes, and its GuardantOMNI test has a 500-gene panel, both of which analyze circulating tumor DNA in blood. Co. has launched its Guardant Reveal liquid biopsy-based tests for residual and recurring cancer to address the need in Stage II-III colorectal cancer. We show 25 historical shares outstanding datapoints in our GH shares outstanding history coverage, used to compute GH market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing GH market cap history over the course of time is important for investors
interested in comparing GH's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of GH versus a peer is one thing; comparing
GH market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like GH can fluctuate over the course of history.
With this page we aim to empower investors researching GH by allowing them to research the GH market cap history. |
Free GH Email Alerts:
Video: The Importance of Market Cap
